Robin Leaper lost her voice to ALS. Artificial Intelligence has given her back the ability to speak with her own voice.

Due to a lack of resources and personnel, the FDA has delayed until October its decision on lifting a clinical hold on ALS ...

A compound normally associated with red blood cells may also play a game-changing antioxidant role in the brain, a study has ...

After three long months, on Aug. 18, Nesbit's Lanes held a celebration marking its grand reopening. Now, a fundraiser for ...

United States of America's Miss Ohio 2025 Tamera Carter will join hundreds of walkers and community partners on Sept. 14 to ...

Scientists have created a lifelike model of Amyotrophic Lateral Sclerosis (ALS), a type of motor neuron disease, using cells ...

Many people will never know the last time they will do certain things in life. Even though he navigates sometimes trying days ...

"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The amyotrophic ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, with an incidence of 1 or 2 cases per 100,000 persons and a lifetime risk of 1 case per 800 persons.